In utero aspirin exposure and child neurocognitive development: A propensity score-matched analysis
- PMID: 38808468
- DOI: 10.1111/1471-0528.17871
In utero aspirin exposure and child neurocognitive development: A propensity score-matched analysis
Abstract
Objective: To evaluate the association between a short-period, high-dose in utero aspirin exposure and child neurocognitive development.
Design: A propensity score-matched analysis of a multicentre prospective cohort study.
Setting: The US Collaborative Perinatal Project (1959-1976).
Population: A total of 50 565 singleton live births with maternal information.
Methods: We performed a propensity score matching to balance maternal characteristics between women with and without aspirin exposure. Inverse probability-weighted marginal structural models were used to estimate associations between aspirin exposure and child neurocognitive assessments.
Main outcome measures: Child neurocognitive development was assessed using the Bayley Scales at 8 months, the Stanford Binet Intelligence Scale at 4 years, and the Wechsler Intelligence Scale and Wide-Range Achievement Test (WRAT) at 7 years.
Results: Children exposed to aspirin in utero were associated with an 8%-16% reduced risk of having suspect/abnormal or below-average scores in most neurocognitive assessments. A trend of lower risks of having suspect/abnormal or below-average scores was further observed in children with in utero aspirin exposure for more than 7 days, particularly on Bayley Mental (relative risk [RR] 0.82, 95% CI 0.74-0.92), WRAT Reading (RR 0.88, 95% CI 0.78-0.98) and WRAT Arithmetic tests (RR 0.76, 95% CI 0.66-0.86). This association was mainly observed in the second trimester of pregnancy.
Conclusions: In utero aspirin exposure was associated with improved child neurocognitive development in a prospective cohort study. Further studies are warranted to evaluate the impact of long-period and low-dose in utero aspirin exposure on child short- and long-term neurodevelopment.
Keywords: antenatal exposure; aspirin; neurocognitive development; propensity score matching.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
-
- Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659.
-
- Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low‐dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double‐blind, placebo‐controlled trial. Lancet. 2020;395(10220):285–293.
-
- Kupka E, Hesselman S, Hastie R, Lomartire R, Wikström AK, Bergman L. Low‐dose aspirin use in pregnancy and the risk of preterm birth: a Swedish register‐based cohort study. Am J Obstet Gynecol. 2023;228(3):336.e1–336.e9.
-
- Lim S, McDougall ARA, Goldstein M, Tuttle A, Hastie R, Tong S, et al. Analysis of a maternal health medicines pipeline database 2000–2021: new candidates for the prevention and treatment of fetal growth restriction. BJOG. 2023;130(6):653–663.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
